Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Drug Discov. 2014 Jan;13(1):39-62. doi: 10.1038/nrd4175.

Therapeutic targeting of EPH receptors and their ligands.

Author information

1
Leukaemia Foundation Research Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland 4029, Australia.
2
Queensland Brain Institute, University of Queensland, Brisbane, Queensland 4072, Australia.
3
Department of Biochemistry and Molecular Biology, Monash University, Victoria 3800, Australia.

Abstract

Critical roles for EPH receptor (EPH)-ephrin signalling in a range of chronic and regenerative diseases are increasingly being recognized. In particular, the complex roles of EPHs and ephrins in tumour growth and progression, and in nerve injury and regeneration have been studied extensively. This has led to considerable progress in developing strategies for their therapeutic targeting, with some anticancer agents already in clinical trials. Promising leads for non-malignant diseases are also emerging, with compelling preclinical data encouraging clinical development. We discuss this rapidly developing area of drug discovery, highlighting the associated challenges and limitations.

PMID:
24378802
DOI:
10.1038/nrd4175
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center